Measuring severity of disease and defining treatment benefit using the Simple Endoscopic Activity Score (SES-CD)



Similar documents
Evidence of Crohn s Disease. Case Presentation

Decision systems in quality registries

TREATING INFLAMMATORY BOWEL DISEASE (IBD) BACKGROUNDER

What are the Unmet Needs in the Management of IBD?

Inflammatory Bowel Disease 2012

Proposal to Establish the Crohn s and Colitis Center at the University of Miami Miller School of Medicine

Risk stratification for colorectal cancer especially: the difference between sporadic disease and polyposis syndromes. Dr. med. Henrik Csaba Horváth

Telemedinsk udvikling

Leukapheresis for inflammatory bowel disease

Understanding Colitis and Crohn s Disease

ESD for colorectal lesions I am in favour. Alessandro Repici, MD Digestive Endoscopy Unit IRCCS Istituto Clinico Humanitas Milano, Italy

How To Treat Colitis With A Combination Of Antibiotics

Top Down vs. Step Up Therapy Biologics in IBD: Treatment Algorithms. Stephen B. Hanauer, M.D. University of Chicago

Gastrointestinal Bleeding

6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality

Early Colonoscopy in Patients with Acute Diverticulitis Simon Bar-Meir, M.D.

Complications that may occur with ulcerative colitis:

Medical Therapy for IBD

Evolution of Barrett s esophagus

2. FRAGESTELLUNGEN DER VORGESTELLTEN ARBEITEN Wirksamkeit der Akupunktur bei ausgewählten Schmerzerkrankungen

Learning Luncheon 7: Endoscopic Mucosal Resection: When, Where and How?

These parameters cannot, at the present time, be determined by non-invasive imaging techniques.

In vitro co-culture model of the inflamed intestinal mucosa

CHEM-E4140 Selectivity 12. Pharma Business

Crohn's disease and pregnancy.

Colorectal Cancer Screening: Update on Bowel Preps

Focus Biobank Inflammatory Bowel Disease

AMERICAN VENOUS FORUM

ACT-RAY and MRI substudy

Clinical Indicator Ages Ages Ages Ages Ages 65+ Frequency of visit as recommended by PCP

Crohn s Disease. What is Crohn s Disease? ho gets Crohn s Disease? hat are the symptoms? What causes Crohn s Disease?

EMR Can anyone do this?

JAK1 and beyond. Investor Presentation January Copyright 2014 Galapagos NV

Terapia con farmaci biologici e non nella. Sandro Ardizzone. Azienda Ospedaliera Fatebenefratelli e. Ospedale di Rilievo Nazionale Milan

Diseases of the Colon. Jack Bragg, D.O., F.A.C.O.I.

Laparoscopic Surgery of the Colon and Rectum (Large Intestine) A Simple Guide to Help Answer Your Questions

Colonoscopy Data Collection Form

Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome

How to report Upper GI EMR/ESD specimens

Management of the new antiplatelets and anticoagulants

Briefing Document. Food and Drug Administration. Center for Drug Evaluation and Research

The Forzani MacPhail Colon Cancer Screening Centre Frequently Asked Questions. What is the Forzani MacPhail Colon Cancer Screening Centre?

Research in IBD at University of Colorado Denver

International Journal of Recent Advances in Multidisciplinary Research Vol. 02, Issue 12, pp , December, 2015

Clinical question: what is the role of colonoscopy in the diagnosis of ischemic colitis?

Classification of gastritis. Pieter Demetter Department of Pathology Erasme University Hospital, Brussels

Probiotics for the Treatment of Adult Gastrointestinal Disorders

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Multiple Technology Appraisal

A Phase 2 Study of Interferon Beta-1a (Avonex ) in Ulcerative Colitis

Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity

Arthritis and Rheumatology Clinics of Kansas Patient Education. Reactive Arthritis (ReA) / Inflammatory Bowel Disease (IBD) Arthritis

ID: C13006 Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis NCT Results Preview Close

EVIDENCE BASED TREATMENT OF CROHN S DISEASE. Dr E Ndabaneze

Classification of Inflammation Activity in Ulcerative Colitis by Confocal Laser Endomicroscopy

Crohn s Disease. What I need to know about. U.S. Department of Health and Human Services

Bridging Techniques. What s between EMR and Traditional Surgery? Elisabeth C. McLemore, MD, FACS, FASCRS

PHARMACOLOGIC MANAGEMENT FOR INFLAMMATORY BOWEL DISEASE: ULCERATIVE COLITIS & CROHN S DISEASE

By Anne C. Travis, M.D., M.Sc. and John R. Saltzman, M.D., FACG Brigham and Women's Hospital Harvard Medical School Boston, MA

Cancer of the Cardia/GE Junction: Surgical Options

American College of Gastroenterology Educational Affairs Committee 2015 Conflicts of Interest

IBS TREATMENT CENTER

UPDATED INVESTOR PRESENTATION June 2015

Crohn's disease and ulcerative colitis

Objective tumor response and RECIST criteria in cancer clinical trials Jian Yu, I3, Indianapolis, Indiana

BOLT Hem/Onc Thought Leader Panel #38 Cancer Immunotherapy

Pharma working capital performance highly variable

Wireless Capsule Endoscopy Corporate Medical Policy

Roche s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy

GUIDELINE Sinusitis. David M. Poetker MD, MA Associate Professor. Division of Rhinology and Sinus Surgery

Histopathology of Crohn s disease and ulcerative colitis

Inflammatory Bowel Disease

Colocutaneous Fistula. Disclosures

What is Barrett s esophagus? How does Barrett s esophagus develop?

Key Findings. Use this report to... The Autoimmune Market Outlook to 2013

Transcription:

Measuring severity of disease and defining treatment benefit using the Simple Endoscopic Activity Score (SES-CD) Jean-Frederic COLOMBEL Icahn Medical School at Mount Sinai, New York

J-F Colombel has served as consultant or advisory board member for Abbvie, ABScience, Amgen, Bristol Meyers Squibb, Celltrion, Danone, Ferring, Genentech, Giuliani SPA, Given Imaging, Janssen, Immune Pharmaceuticals, Medimmune, Merck & Co., Millenium Pharmaceuticals Inc., Neovacs, Nutrition Science Partners Ltd., Pfizer Inc. Prometheus Laboratories, Protagonist, Receptos, Sanofi, Schering Plough Corporation, Second Genome, Shire, Takeda, Teva Pharmaceuticals, Tigenix, UCB Pharma, Vertex, Dr. August Wolff GmbH & Co. J-F Colombel has served as speaker for Abbvie, Falk, Ferring, Janssen, Merck & Co., Nutrition Science Partners Ltd., Takeda. 2

The CDEIS Deep ulcerations 12 points Superficial ulcerations 6 points Surface of ulcerations (0-10 cm) Surface of lesions* (0-10 cm) Ileum 0 or 12 0 or 6 0-10 0-10 Right colon 0 or 12 0 or 6 0-10 0-10 Transverse 0 or 12 0 or 6 0-10 0-10 Left colon 0 or 12 0 or 6 0-10 0-10 Rectum 0 or 12 0 or 6 0-10 0-10 TOTAL (sum of all cases) TOTAL/number of explored segments N/1-5 + 3 if ulcerated stenosis 0-3 + 3 if nonulcerated stenosis 0-3 CDEIS : 0 to 44 Mary JY et al. Gut 1989 N : pseudopolyp healed ulcer frank erythema frankly swollen mucosa aphtoid ulcers : 2-3mms 3

Development of SES-CD The Simple Endoscopic Score for Crohn s Disease (SES-CD), was developed in 2004 and was: an attempt to simplify the CDEIS based on importance and reproducibility of the most relevant endoscopic characteristics of CD. Daperno M et al. Gastrointest. Endosc 2004 4

THE SIMPLE ENDOSCOPIC SCORE FOR CD (SES-CD) Definition - scoring of elementary lesions considered SES-CD values (evaluated for each of the 5 ileo-colonic segments) Variable 0 1 2 3 Size of ulcers Ulcerated surface Affected surface Presence of narrowings Unaffected segment Daperno et al. Gastrointest Endosc 2004 5

THE SIMPLE ENDOSCOPIC SCORE FOR CD (SES-CD) Definition - scoring of elementary lesions considered SES-CD values (evaluated for each of the 5 ileo-colonic segments) Variable 0 1 2 3 Size of ulcers Aphtous ulcers ( 0.1 to 0.5 cm) Large ulcers ( 0.5 to 2 cm) Very large ulcers ( >2 cm) Ulcerated surface Affected surface Unaffected segment Presence of narrowings Daperno et al. Gastrointest Endosc 2004 6

THE SIMPLE ENDOSCOPIC SCORE FOR CD (SES-CD) Definition - scoring of elementary lesions considered SES-CD values (evaluated for each of the 5 ileo-colonic segments) Variable 0 1 2 3 Size of ulcers Aphtous ulcers ( 0.1 to 0.5 cm) Large ulcers ( 0.5 to 2 cm) Very large ulcers ( >2 cm) Ulcerated surface <10% 10-30% >30% Affected surface Presence of narrowings Unaffected segment Daperno et al. Gastrointest Endosc 2004 7

THE SIMPLE ENDOSCOPIC SCORE FOR CD (SES-CD) Definition - scoring of elementary lesions considered SES-CD values (evaluated for each of the 5 ileo-colonic segments) Variable 0 1 2 3 Size of ulcers Aphtous ulcers ( 0.1 to 0.5 cm) Large ulcers ( 0.5 to 2 cm) Very large ulcers ( >2 cm) Ulcerated surface <10% 10-30% >30% Affected surface Presence of narrowings Unaffected segment <50% 50-75% >75% Daperno et al. Gastrointest Endosc 2004 8

THE SIMPLE ENDOSCOPIC SCORE FOR CD (SES-CD) Definition - scoring of elementary lesions considered SES-CD values (evaluated for each of the 5 ileo-colonic segments) Variable 0 1 2 3 Size of ulcers Aphtous ulcers ( 0.1 to 0.5 cm) Large ulcers ( 0.5 to 2 cm) Very large ulcers ( >2 cm) Ulcerated surface <10% 10-30% >30% Affected surface Unaffected segment <50% 50-75% >75% Presence of narrowings Single, can be passed Multiple, can be passed Cannot be passed Daperno et al. Gastrointest Endosc 2004 Daperno et al. Gastrointest Endosc 2004; 60:505-129

THE SIMPLE ENDOSCOPIC SCORE FOR CD (SES-CD) Ileum Right colon Transverse colon Left colon Rectum Total Presence and size of ulcers (0-3) 0-3 0-3 0-3 0-3 0-3 0-15 Extent of ulcerated surface (0-3) 0-3 0-3 0-3 0-3 0-3 0-15 Extent of affected surface (0-3) 0-3 0-3 0-3 0-3 0-3 0-15 Presence and type of narrowings (0-3) 0-3 0-3 0-3 0-3 0-3 0-11 SES-CD = 0-56 Daperno et al. Gastrointest Endosc 2004 10

Correlation between CDEIS and SES-CD Sipponen T et al. Inflam Bowel Dis 2010 11

Definition of endoscopic severity using SES-CD Endoscopic severity with SES-CD (in 4 of 11 studies)* : remission (inactive) (0-2) mild inflammation (3-6) moderate inflammation (7-15) severe inflammation (> or =16) * In total 6 different cut-off definitions, but 6 of 11 studies used similar cutoffs Vuiiton L et al. in preparation 12

SES-CD grading vs CDEIS grading SES-CD overestimates severity vs CDEIS in inactive / mild CD Sipponen T et al. Inflam Bowel Dis 2010 13

Definition of endoscopic response with SES-CD Authors Journal Year Definition of response Sipponen et al. Scand J Gastroenterol 2010 A partial response as a one-class change in the SES-CD (inactive 0-2; mild 3-6; moderate 7-15; severe > or =16) Ferrante et al. (SONIC post hoc) Gastroenterology 2013 Decrease from baseline in SES-CD of at least 50%. Grover et al. J Gastroenterol 2014 Absolute score SES-CD 0-3 was defined as a response 14

Endoscopic response at wk 26 predicts corticoid-free remission at wk 50 in CD (SONIC) Roc Curve for detecting corticoid-free remission at wk 50 using the SES-CD % reduction from baseline to wk 26 Roc Curve for detecting corticoid-free remission at wk 50 using the CDEIS % reduction from baseline to wk 26 Endoscopic response (defined as a decrease from baseline in SES-CD or CDEIS of at least 50%) at week 26 identified patients most likely to be in CFREM at week 50 Ferrante M, et al. Gastroenterology; 2013 15

Definition of endoscopic response with SESCD Endoscopic response using SES-CD* A decrease from baseline in SES-CD of at least 50%. 1 * In total 3 different definitions in 3 studies 1 Ferrante et al. GASTROENTEROLOGY 2013 16

Definition of endoscopic remission using SES-CD Authors Journal Year Definition of Remission Moskovitz et al. Gastroenterology 2007 score 0 Sipponen et al. Aliment Pharmacol Ther 2008 score <3 Baert et al. Gastroenterology 2010 score 0 Sipponen et al. Scand J Gastroenterol 2010 score 0 2 or a two- or three-class decrease in the SES-CD from the baseline score ( i.e. change from endoscopically severely active disease to mildly active or inactive or from moderately active to inactive). Aomatsu et al. Aliment Pharmacol Ther 2011 score 0 Aomatsu et al. Dig Dis Sci 2011 score 0 af Björkesten et al. Scand J Gastroenterol 2013 score 0-2 Molander et al. J Crohns Colitis 2013 score 0-2 Beigel et al. PLoS One 2014 score 0 Fukuchi et al. BMC Gastroenterol 2014 score 0 Yüksel et al. Turk J Gastroenterol 2014 score 0-2 Yu et al. J Dig Dis 2014 score 0 Schaffer et al. J Crohns Colitis 2014 score 0-3 Dignass et al. J Crohns Colitis 2014 score 0 17

Definition of endoscopic remission/mh using SES-CD Endoscopic remission/mh most frequently defined as* SES-CD score 0 (8 studies) or SES-CD score 0-2 (4 studies) * In total 4 different cut-off definitions in 14 studies 18

IOIBD recommendations on endoscopic indices Methods of the IOIBD Consensus 12 IBD experts from 9 countries Literature reviewing Extracted definitions of endoscopic outcome parameters for remission and response in UC and CD Delphi process based on an internet survey At each voting step, participants blinded from others Vuiiton L et al. in preparation 19

IOIBD recommendations on endoscopic response For the definition of endoscopic response in CD retained for vote were : 1. Any improvement in edema, erythema, ulcers and strictures 2. Only mucosal patchy erythema or superficial ulceration ; 3. Near complete healing: erosions if previous large ulcers/partial healing if >33% reduction in ulcer size 4. Decrease in CDEIS (with no definition) 5. Decrease in CDEIS > 5 6. Decrease in SES-CD (ND) 7. Decrease in CDEIS of at least 3 points 8. >75 % decrease in CDEIS 9. > 50% decrease in SES-CD or CDEIS 10. Decrease in CDEIS > 4 or 5 20

IOIBD recommendations on endoscopic response For the 10 proposed definitions of endoscopic response in CD at the first vote 11 out of 12 investigators ranked first > 50% decrease in SES-CD No second round was organized due to the high agreement in the first voting round. 21

IOIBD recommendations on endoscopic remission 1. For definition of endoscopic remission in CD: 1. Physician assessment of endoscopic healing 2. Absence of edema, erythema, ulcers and strictures 3. No lesion, only scarred lesions, or minor lesions with no deep ulceration 4. Normal mucosa, scarring or pseudo polyps 5. Complete healing : no endoscopic lesion 6. Near complete healing: only aphtous ulcers <5mm 7. Endoscopic remission :CDEIS < 6 / Complete endoscopic remission : CDEIS <3 8. Absence of ulceration 9. Complete healing: resolution of all lesions/ Near complete healing :occasional aphthae, residual erosion, thickened folds 10. SES-CD : 0-2 11. CDEIS score of 4 or less 12. CDEIS < 6 or 7 * No proposed definition of SES-CD = 0 22

IOIBD recommendations on endoscopic remission For the 12 proposed definitions of endoscopic remission in CD, the four definitions with the highest rank after the 1 st vote were : (1) SES-CD 0-2 (2) remission: CDEIS < 6 / complete remission : CDEIS <3 (3) absence of ulceration (4) CDEIS score of 4 or less. At the second vote the highest median score was : SES-CD 0-2 (median1, mean1.33, SD 0.49), with 100 % of the experts ranking this definition first or second. 23